How Value Analysis Committees Define Medical Device Market Access (And What to Show Them)

2026-09-11 · Caduvo Team

Hospital value analysis committees decide whether your device gets used—and they ask for clinical outcomes and hard cost numbers, not FDA clearance letters. Learn the evidence and the go-to-market sequence that turns a cleared device into an adopted one.

Hospital value analysis committees don’t care about your FDA clearance letter. They want to know if your device saves time, prevents complications, or bends the cost curve in a way the hospital owns. That shift—from regulatory approval to economic buying behavior—is what medical device market access actually means.

A 510(k) or De Novo gets you into the country. It doesn’t get you onto a shelf, into a preference card, or paid outside a bundled DRG. Market access is the intersection of coding, coverage, payment, and local adoption. For most devices, the final gate is the value analysis committee (VAC).

What a Value Analysis Committee Decides

A VAC is a standing hospital panel—usually a mix of supply chain, finance, nursing, and physician leadership. They review every new product request that costs more than the current standard or touches a high-spend service line. Their job: approve, reject, or restrict.

They don’t read 510(k) summaries. They read a business case: upfront acquisition cost, any savings from length-of-stay reduction or fewer readmissions, and whether the device requires new training or changes sterile processing workflow. If your product is more expensive per unit but reduces OR time by 12 minutes, they’ll ask what that OR minute costs and whether the freed time actually gets used for another case.

The Evidence Buyers Actually Ask For

When a VAC gets your dossier, the first three questions are almost always:

For clinical evidence, a single-center retrospective chart review won’t move the needle. They look for peer-reviewed data from a comparable setting—ideally a study showing a reduction in a complication they track, like surgical site infections or ventilator days. If you’re pre-revenue, a well-designed budget impact model built from hospital cost accounting data (OR supply cost, nursing time, length-of-stay averages) can still open a conversation.

Economic evidence divides into two buckets: cost to the hospital and cost to the payer. VACs own the hospital side. A device that shortens post-op stay by one day saves the hospital roughly $1,200–$2,400 in direct costs, depending on the unit. If your product costs $800 more than the incumbent, that math closes quickly. Spell it out in a one-page table: current-state episode cost vs. new-device episode cost. Don’t bury the buyer in ICER calculations.

Supply chain data matters too. Your product has a UDI, might compete with a GPO-contracted item, and will sit in the warehouse. If you don’t know the existing contract tier and your product’s packaging footprint, the VAC will table the request. You don’t need perfect data; you need answers that show you’ve done the logistics homework.

The Real Go-to-Market Sequence for a First Product

Too many small device companies chase a CPT code and Medicare coverage before they have hospital-level evidence. That’s backwards. A realistic medtech market access sequence for a hospital-purchased device looks like this:

  1. Clinical signal generation. Before FDA submission, run a small observational study or a first-in-human trial that captures resource utilization—procedure time, complications, discharge disposition. Even 30 patients can produce a defensible time-and-motion dataset.
  2. Coding foundation. Determine whether you need a new CPT Category I application (multi-year, requires AMA adoption) or can use an existing code plus a HCPCS level II code for a pass-through or DME payment. Early coding work prevents a dead year post-clearance where nobody can bill for your device.
  3. Payer engagement, sequenced by pressure. Start with regional payers that control the hospitals where your KOLs practice. Use your clinical data to request a coverage policy or a case-rate adjustment. Medicare national coverage is a marathon; a local LCD or a commercial policy that recognizes the technology as medically necessary often comes faster and unlocks enough volume to generate more evidence.
  4. VAC readiness package. Build the dossier while payer conversations are underway. Include the clinical evidence summary, a hospital-specific budget impact model, a sample order set with utilization criteria, and a list of three comparable sites already using the device. If you have no sites, offer a structured evaluation period with agreed-upon metrics.
  5. Hospital introduction. Don’t lead with the sales rep. Lead with a clinical champion who presents the evidence at a VAC meeting. Most committees meet monthly and will not consider a product without a physician sponsor. Once approved, negotiate a quick trial to collect real-world data that feeds back into the payer argument.

This sequence works because each step produces the evidence the next step needs. Pilot data supports coding. Coding enables payer asks. Payer wins and site data give the VAC the confidence that the device isn’t just cleared—it’s covered, reimbursed, and operationally feasible.

What Changes When You Sell a Non-Implantable or Office-Based Device

The VAC dynamic shifts if your device is used in a physician office, an ambulatory surgery center, or directly by patients (DME). In those settings, the physician or the DME supplier is the economic buyer, not the hospital VAC. However, market access still hinges on coding and coverage first. Without a properly established HCPCS code and a Medicare fee schedule assignment, large commercial payers won’t process claims. DME billing requires specific code pairs and competitive bidding compliance; missing either kills adoption.

For office-based procedures, the physician practice manager will ask a different version of the value question: “Does this add a separately billable service, or does it replace a supply I already buy?” The CPT code you use and the relative value units (RVUs) it carries dictate whether the practice sees a net revenue gain or just a higher expense. Know the practice economics before you walk in.

Keep Your Evidence Story Tight

VAC members see dozens of new-product requests each quarter. They’ll give your submission 12 minutes. Everything you present should fit into three buckets: clinical improvement (with a number), hospital cost impact (with a number), and implementability (who touches it, where it stores, how it bills). If you can’t put a credible dollar amount or an outcome percentage on the table, you’re not ready for the meeting.

Tools that organize payer policies and code pathways can speed up the preparation, but the VAC decision still turns on the numbers you bring. For the specific evidence they expect, earlier is better: start collecting utilization and cost data while you’re still generating the clinical endpoints your FDA submission needs.

Actionable Takeaways

Related reading